CNS Pharmaceuticals Q2 GAAP EPS misses estimates by $0.13

Earnings
โดย Seeking Alpha·US·Read original
Summary · why it matters

CNS Pharmaceuticals reported a second-quarter GAAP loss of $0.37 per share, missing analyst estimates by $0.13. Cash and cash equivalents rose to approximately $20.0 million as of June 30, 2026, up from $7.2 million at the end of 2025, driven mainly by a private placement completed in May 2026. The company believes its existing cash resources are sufficient to fund planned operations beyond the next twelve months as it continues executing its strategic business development initiatives.

Impact on stocks 1

Biotech & Genomic Medicine▼ · 1 stocks
© 2026 MarketDXNews